Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3, indicating a software version update for the site. This update does not change the displayed trial information or how users interact with the page.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3 on the page, indicating a software deployment update.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2 on the page. This minor version update does not change any study information or user-facing content.SummaryDifference0.1%

- Check53 days agoChange DetectedInvestigator attribution was split into a standalone name entry and new metadata lines (Last verified, Last known status). The page also introduces new help sections (How to Read a Study Record, Common Questions, How to Join a Study) and a standardized label for Intervention/Treatment.SummaryDifference2%

- Check60 days agoChange DetectedA new revision tag labeled Revision: v3.5.5 appears, replacing the prior Revision: v3.5.4.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page now displays Revision: v3.5.4, updating the revision label from the previous v3.5.3. This reflects a new entry in the page's revision history.SummaryDifference0.1%

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.